<DOC>
	<DOCNO>NCT00132392</DOCNO>
	<brief_summary>ALGRX 4975 placebo drip onto cut muscle soft tissue end surgery total replacement knee . Each subject undergo screen visit ; hospitalization , total replacement knee perform ; follow-up visit 2 , 6 , 12 week surgery . In addition , discharge , subject contact telephone daily Day 14 . Subjects complete pain medication diary first 2 week follow surgery return diary 2 week visit . Starting afternoon Day 0 ( day surgery ) , pain active range motion ( ROM ) operate knee measure morning 8 AM ± 2 hour afternoon 3 PM ± 3 hour . In addition , subject ambulates , pain ambulation measure first ambulation morning first ambulation noon . Subjects complete Brief Pain Inventory - Short Form ( BPI-SF ) preoperatively , 2 , 6 , 12 week visit . Subjects question regard use assistive device ( cane , walker , wheelchair , bedside commode , assistive device ) screening , discharge , 2 , 6 , 12 week visit . The active ROM flexion knee , measure use goniometer , record screen 2 week visit . Sensory mapping knee perform screen 12 week visit .</brief_summary>
	<brief_title>ALGRX 4975 After Total Knee Replacement</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , study conduct subject undergoing unilateral TKA . Subjects undergo screen visit 28 day prior surgery . A sufficient number subject enrol obtain least 40 evaluable subject . Upon enrollment , subject randomized 1:1 ratio ALGRX 4975 placebo . Subjects receive femoral nerve block prior induction general anesthesia . Subjects undergo total knee arthroplasty ( TKA ) general anesthesia . Prior closure surgical wound , single dose ALGRX 4975 5 mg 60 mL placebo instill ( dripped syringe approximately 1 minute ) wind onto cut muscle soft tissue allow dwell 5 minute . The Investigator inject bupivacaine 0.25 % 40 mL area wound cut muscle close wind usual surgical procedure . Postoperative pain manage morphine sulfate administer intravenously patient control analgesia ( PCA ) . Following discontinuation PCA pump , subject provide hydrocodone 7.5 mg/acetaminophen 500 mg postoperative pain . Each subject undergo screen visit ; hospitalization , TKA perform ; follow-up visit 2 , 6 , 12 week surgery . Subjects receive twice daily examination hospitalize TKA procedure . In addition , discharge , subject contact telephone daily Day 14 , remind complete pain medication diary , 4 week surgery follow-up . Subjects complete pain medication diary first 2 week follow surgery return diary 2 week visit . Starting afternoon Day 0 ( day surgery ) , pain active range motion ( ROM ) operate knee measure use 11 point numerical rating scale ( NRS ) morning 8 AM ± 2 hour afternoon 3 PM ± 3 hour , within one hour physical therapy . In addition , subject ambulates , pain ambulation measure first ambulation morning first ambulation noon . Subjects complete Brief Pain Inventory - Short Form ( BPI-SF ) preoperatively , 2 , 6 , 12 week visit . Subjects question regard use assistive device ( cane , walker , wheelchair , bedside commode , assistive device ) screening , discharge , 2 , 6 , 12 week visit . The active ROM flexion knee , measure use goniometer , record screen 2 week visit . Sensory mapping knee perform screen 12 week visit .</detailed_description>
	<mesh_term>Knee Injuries</mesh_term>
	<criteria>The subject ( male female ) age 35 80 year . Female subject childbearing potential must negative serum urine pregnancy test within 24 hour prior administration study drug ; must nonlactating ; must willing use adequate reliable contraception throughout study . The subject plan undergo unilateral TKA . The subject willing able understand study procedure use pain scale , communicate meaningfully study personnel . The subject good health capable undergoing TKA . The subject sign Informed Consent approve Institutional Review Board ( IRB ) . The subject laboratory test value outside accepted range unless approve Sponsor . The subject currently take take chronic opioid ( 30 consecutive day daily use ) pain knee pain past two year . The use capsaicin , opioids , bupivacaine , ropivacaine , muscle relaxant , acetaminophen contraindicate subject ( e.g. , significant history allergic reaction intolerance related substance ) . The use general anesthesia contraindicate subject . The subject take central nervous system ( CNS ) active drug benzodiazepine , tricyclic antidepressant , selective serotonin reuptake inhibitor ( SSRIs ) pain . These drug permit nonpain indication dose stable least 30 day . The use nonsteroidal antiinflammatory drug ( NSAIDs ) acetaminophen permit stable least 30 day . The use lorazepam sleep medication permit . Administration ketorolac tromethamine ( Toradol® ) permit preoperatively , intraoperatively , postoperatively later 8 PM day surgery . The subject medical condition , Investigator ’ opinion , could adversely impact subject ’ participation safety ; conduct study ; interfere pain assessment , include fracture active infection . The subject diabetes mellitus HbA1C &gt; 9.5 history prolong uncontrolled diabetes . The subject another painful physical condition , opinion Investigator , may confound assessment postoperative pain rehabilitation . The subject history current neuropathic pain condition . The subject plan undergo bilateral TKA . The subject arthroplasty ( partial total ) index knee . The subject history drug , prescription medicine alcohol abuse within past 2 year . The subject take antihypertensive agent diabetic regimen dose stable least 30 day The subject take following medication : digoxin ; antiarrhythmic except betablockers ; warfarin ; theophylline preparation ; aminoglycosides ; anticonvulsant except benzodiazepine ; lithium . The subject take investigational product within 3 month prior first dose study drug ( Visit 2 ) , schedule receive investigational product ALGRX 4975 , participate study . The subject know bleed disorder take agent affect coagulation . Low dose aspirin allow cardiac prophylaxis ; NSAIDs , stable least 30 day , permit ; deep venous thrombosis prophylaxis , surgeon ’ choice , permit postoperatively . The subject previously participate clinical study ALGRX 4975 .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Arthroplasty</keyword>
	<keyword>Total knee arthroplasty</keyword>
	<keyword>Capsaicin</keyword>
	<keyword>Pain</keyword>
	<keyword>Analgesia</keyword>
</DOC>